Showing results (111-120 of 529) with videos related to

Sort By:
Pageof 53
European Heart Journal. Cardiovascular Pharmacotherapy|December 5, 2021
Cardiovascular risks associated with use of non-steroidal anti-inflammatory drugs in patients with non-obstructive coronary artery diseaseNatascha Gaster, Lars Pedersen, Vera Ehrenstein, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 10, 2019
How to implement the recommendations of the 2018 ESC/ESH Hypertension Guidelines in a given patient: a step by step approachAntonio Coca, Monica Doménech
European Heart Journal. Cardiovascular Pharmacotherapy|September 13, 2019
P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projectsOvidio De Filippo, Fabrizio D'Ascenzo, Sergio Raposeiras-Roubin, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 20, 2021
Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillationSo-Ryoung Lee, Eue-Keun Choi, Sang-Hyun Park, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 18, 2022
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19Bertram Pitt, Ashley M Tate, David Gluck, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 12, 2019
Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trialYing-Ying Zheng, Ting-Ting Wu, Yi Yang, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 17, 2019
Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudyTania Sharma, Rebecca Rylance, Sofia Karlsson, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 20, 2022
Effects of renin-angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantationUlrich Fischer-Rasokat, Celine Bänsch, Matthias Renker, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyJuan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 24, 2022
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysisWaqas Ullah, Salman Zahid, Harigopal Sandhyavenu, et al.
Pageof 53